TGM-148 / Tangram Therapeutics - LARVOL DELTA

Preclinical Safety and Thrombotic Risk Assessment of the siRNA TGM-148 for Bleeding Disorders (ISTH 2026) - "mTGM- 148 was co-administered with standard factor replacement therapies (Advate, BeneFIX) or bypassing agents (NovoSeven, FEIBA), with measurement of D-dimer levels. TGM-148 is advancing toward CTA submission in 2026. DOI*10.1016/j.rpth.2026.104873"

Preclinical • Cardiovascular • Hematological Disorders • Hemophilia • Hemophilia A • Hemophilia B • Rare Diseases • Thrombosis

e-therapeutics to Present Preclinical Data on ETX-148 at EAHAD 2025 (GlobeNewswire) - "e-therapeutics plc...announced today that it will present new preclinical data demonstrating efficacy and safety of ETX-148 in murine models of haemophilia A and B at the Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), 4th-7th February 2025. ETX-148 is being developed for the treatment of bleeding disorders and is currently progressing through IND-enabling studies, with an IND submission anticipated during 2026."

IND • Preclinical • Hemophilia A • Hemophilia B

Efficacy and Safety of ETX-148 in Murine Models of Haemophilia A and B (EAHAD 2025) - No abstract available

Preclinical • Hematological Disorders • Hemophilia • Hemophilia A • Hemophilia B • Rare Diseases